TFE3 and carcinoma: Coupled with selection for biomarkers specific to sarcoma subtypes such as TLE1 or ASPL-TFE3, the ApoStream® device will facilitate CTC isolation and analysis for anticancer drug development, longitudinal monitoring of pharmacodynamic drug effects, and disease management for patients with carcinoma or sarcoma alike.